The primary purpose of this Commentary is to complement the description of biomarkers given in this issue in the Pharmaceutical Research and Manufacturers of America report by Lathia et al. I offer several examples of the use of biomarkers that highlight their value in drug development and regulatory decision making. Clinical Pharmacology & Therapeutics (2009); 86, 1, 26–27 doi:10.1038/clpt.2009.57
No takes yet. Share an insight, caveat, or question.
JVS Gobburu (2009) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: